Overview

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma. PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
West of Scotland Lymphoma Group
Treatments:
Dexamethasone
Doxorubicin
Idarubicin
Liposomal doxorubicin
Vincristine